Increased vitamin D binding protein levels
are associated with irritable bowel
syndrome

BÖREKÇİ, Hasan; BAŞ, Hatice; YILDIRIM, Tekin; Kılıç, Mahmut; GÖÇMEN, Yeşim; Börekci, Elif; OZAN, Zeynep

doi:10.1515/tjb-2020-0305

Increased vitamin D binding protein levels are associated with irritable bowel syndrome

Elif BÖREKÇİ, (Celal Bayar Üniversitesi Tıp Fakültesi, Manisa, Türkiye)

Mahmut KILIÇ, (Bozok Üniversitesi Fakültesi Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, Yozgat, Türkiye)

Zeynep OZAN, (Bozok Üniversitesi Tıp Fakültesi, Dahiliye Anabilim Dalı Yozgat, Türkiye)

Hasan BÖREKÇİ, (Bozok Üniversitesi Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Yozgat, Türkiye)

Tekin YILDIRIM, (Bozok Üniversitesi Tıp Fakültesi, Dahiliye Anabilim Dalı, Yozgat, Türkiye)

Yeşim GÖÇMEN, (Bozok Üniversitesi Fakültesi Tıp Fakültesi, Biyokimya Bölümü, Yozgat, Türkiye)

Hatice BAŞ (Bozok Üniversitesi Güzel Sanatlar Fakültesi, Biyoloji Bölümü, Yozgat, Türkiye)

Türk Biyokimya Dergisi

4 0

Yıl: 2021 Cilt: 46 Sayı: 4 Sayfa Aralığı: 415 - 424 Metin Dili: İngilizce DOI: 10.1515/tjb-2020-0305 İndeks Tarihi: 24-06-2022

Increased vitamin D binding protein levels are associated with irritable bowel syndrome

Öz:

identify Irritable bowel syndrome (IBS) and its subtypes. The aim of this study is to explore potential serum biomarkers that may be associated with IBS subtypes, particularly in the vitamin D pathway. Methods: The study population comprised 75 IBS patients and 79 controls. Patients divided into IBS subtypes. Routine biochemical parameters, 25-OH-vitamin D, vitamin D binding protein (VDBP) and vitamin D receptor (VDR) serum levels were compared between IBS subtypes and controls. Factors related to IBS subtypes were examined by multivariate logistic regression analysis. Results: Vitamin D levels were lower; VDBP and VDR were higher in all IBS patients than in controls (p<0.001; 0.047 and 0.029, respectively). According to logistic regression analysis, VDBP was a disease-related parameter as much as vitamin D in all IBS subtypes. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were higher especially in diarrhea-dominant IBS (IBS-D) (p=0.041; 0.046) and vitamin B12 were significantly lower in constipation-dominant IBS (IBS-C) (p=0.001). Conclusions: Increased VDBP levels were associated with all IBS subtypes. Patients, especially in IBS-D, had higher serum levels of VDBP, CRP and ESR. Vitamin B12 deficiency, which we consider as a result of the disease, was more common in IBS-C.

Anahtar Kelime:

Artmış D vitamini bağlayıcı protein seviyeleri İrritabl barsak sendromu ile ilişkilidir

Öz:

Amaç: İrritabl barsak sendromu (IBS) ve alt tiplerini tanımlamak için güvenilir ve geçerli bir biyobelirteç yoktur. Bu çalışmanın amacı, özellikle D vitamini yolağında IBS alt tipleri ile ilişkili olabilecek potansiyel serum biyobelirteçlerini araştırmaktır. Gereç ve Yöntem: Çalışma popülasyonu 75 IBS hastası ve 79 kontrolden oluşmuştur. Hastalar IBS alt tiplerine ayrılmıştır. IBS alt tipleri ve kontroller arasında rutin biyokimyasal parametreler, 25-OH-vitamin D, vitamin D bağlayıcı protein (VDBP) ve vitamin D reseptörü (VDR) serum seviyeleri karşılaştırılmıştır. IBS alt tipleri ile ilişkili faktörler çok değişkenli lojistik regresyon analizi ile incelenmiştir. Bulgular: Tüm IBS hastalarında kontrollere göre D vitamini seviyeleri daha düşük, VDBP ve VDR seviyeleri daha yüksekti (sırasıyla p<0.001; 0.047 ve 0.029). Lojistik regresyon analizine göre VDBP, tüm IBS alt tiplerinde D vitamini kadar hastalıkla ilişkili bir parametre idi. C-reaktif protein (CRP) ve eritrosit sedimentasyon hızı (ESR), özellikle ishal baskın IBS’de (IBS-D) daha yüksekti (p=0.041; 0.046) ve vitamin B12, kabızlık baskın IBS’de (IBS-C) anlamlı olarak daha düşüktü (p=0.001). Sonuçlar: Artmış VDBP seviyeleri tüm IBS alt tipleri ile ilişkiliydi. Özellikle IBS-D’deki hastalar daha yüksek VDBP, CRP ve ESR seviyelerine sahipti. Hastalığın sonucu olarak gördüğümüz B12 vitamini eksikliği IBS-C’de daha sık idi.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262–79.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21.
3. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology 2016;150:1393–407.
4. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345:37–42.
5. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a lowgrade inflammatory bowel disease? Gastroenterol Clin N Am 2005;34:235–45.
6. Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017;6:99.
7. Tazzyman S, Richards N, Trueman AR, Evans AL, Grant VA, Garaiova I, et al. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. BMJ Open Gastroenterol 2015;2:e000052.
8. Abbasnezhad A, Amani R, Hajiani E, Alavinejad P, Cheraghian B, Ghadiri A. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. Neuro Gastroenterol Motil 2016;28:1533–44.
9. Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl 2005;76:11–20.
10. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33–42.
11. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metabol 2000;11:320–7.
12. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013;92:77–98.
13. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008;294:208–16.
14. Li YC, Chen Y, Du J. Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. J Steroid Biochem Mol Biol 2015;148:179–83.
15. Lisowska-Myjak B, Jóźwiak-Kisielewska A, Łukaszkiewicz J, Skarżyńska E. Vitamin D-binding protein as a biomarker to confirm specific clinical diagnoses. Expert Rev Mol Diagn 2020; 20:49–56.
16. Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, et al. Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice. United European Gastroenterol J 2017;5:773–88.
17. Self MM, Czyzewski DI, Chumpitazi BP, Weidler EM, Shulman RJ. Subtypes of irritable bowel syndrome in children and adolescents. Clin Gastroenterol Hepatol 2014;12:1468–73.
18. Sprake EF, Grant VA, Corfe BM. Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data. Case Rep 2012;2012:bcr-2012-007223. https://doi.org/10.1136/bcr-2012-007223.
19. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Proinflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 2012;33:251–6.
20. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet 2016;1:133–46.
21. Hauser G, Tkalcic M, Pletikosic S, Grabar N, Stimac D. Erythrocyte sedimentation rate – possible role in determining the existence of the low grade inflammation in irritable bowel syndrome patients. Med Hypotheses 2012;78:818–20.
22. Bjorkhem-Bergman L, Torefalk E, Ekstrom L, Bergman P. Vitamin D binding protein is not affected by high-dose vitamin D supplementation: a post hoc analysis of a randomised, placebocontrolled study. BMC Res Notes 2018;11:619.
23. Kew RR. The vitamin D binding protein and inflammatory injury: a mediator or sentinel of tissue damage? Front Endocrinol 2019;10: 470.
24. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metabol 2000;11:320–7.
25. Guha C, Osawa M, Werner PA, Galbraith RM, Paddock GV. Regulation of human Gc (vitamin D-binding) protein levels: hormonal and cytokine control of gene expression in vitro. Hepatology 1995;21:1675–81.
26. Chalmers JD, McHugh BJ, Docherty C, Govan JRW, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013;68:39–47.
27. Wood AM, Bassford C, Webster D, Newby P, Rajesh P, Stockley RA, et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011;66:205–10.
28. Rinaldi AO, Sanseverino I, Purificato C, Cortese A, Mechelli R, Francisci S, et al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins 2015;7:129–37.
29. Yang M, Qin Z, Zhu Y, Li Y, Qin Y, Jing Y, et al. Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression. Mol Neurobiol 2013;47:946–56.
30. Gasparri C, Curcio A, Torella D, Gaspari M, Celi V, Salituri F, et al. Proteomics reveals high levels of vitamin D binding protein in myocardial infarction. Front Biosci (Elite Ed) 2010;2:796–804.
31. Owolabi O, Agbla S, Owiafe P, Donkor S, Togun T, Sillah AK, et al. Elevated serum 25-hydroxy (OH) vitamin D levels are associated with risk of TB progression in Gambian adults. Tuberculosis 2016; 98:86–91.
32. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, et al. Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes 2011;60:2566–70.
33. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009;7:28.
34. Speeckaert MM, Wehlou C, Vandewalle S, Taes YE, Robberecht E, Delanghe JR. Vitamin D binding protein, a new nutritional marker in cystic fibrosis patients. Clin Chem Lab Med 2008;46:365–70.
35. Kongsbak M, Levring TB, Geisler C, von Essen MR. The vitamin d receptor and T cell function. Front Immunol 2013;4:148.
36. Chandar AK. Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med 2017;10:385–93.
37. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;21: 1391–5.
38. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol 2007;3:112–22.

APA	Börekci E, Kılıç M, OZAN Z, BÖREKÇİ H, YILDIRIM T, GÖÇMEN Y, BAŞ H (2021). Increased vitamin D binding protein levels are associated with irritable bowel syndrome. , 415 - 424. 10.1515/tjb-2020-0305
Chicago	Börekci Elif,Kılıç Mahmut,OZAN Zeynep,BÖREKÇİ Hasan,YILDIRIM Tekin,GÖÇMEN Yeşim,BAŞ Hatice Increased vitamin D binding protein levels are associated with irritable bowel syndrome. (2021): 415 - 424. 10.1515/tjb-2020-0305
MLA	Börekci Elif,Kılıç Mahmut,OZAN Zeynep,BÖREKÇİ Hasan,YILDIRIM Tekin,GÖÇMEN Yeşim,BAŞ Hatice Increased vitamin D binding protein levels are associated with irritable bowel syndrome. , 2021, ss.415 - 424. 10.1515/tjb-2020-0305
AMA	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H Increased vitamin D binding protein levels are associated with irritable bowel syndrome. . 2021; 415 - 424. 10.1515/tjb-2020-0305
Vancouver	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H Increased vitamin D binding protein levels are associated with irritable bowel syndrome. . 2021; 415 - 424. 10.1515/tjb-2020-0305
IEEE	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H "Increased vitamin D binding protein levels are associated with irritable bowel syndrome." , ss.415 - 424, 2021. 10.1515/tjb-2020-0305
ISNAD	Börekci, Elif vd. "Increased vitamin D binding protein levels are associated with irritable bowel syndrome". (2021), 415-424. https://doi.org/10.1515/tjb-2020-0305

APA	Börekci E, Kılıç M, OZAN Z, BÖREKÇİ H, YILDIRIM T, GÖÇMEN Y, BAŞ H (2021). Increased vitamin D binding protein levels are associated with irritable bowel syndrome. Türk Biyokimya Dergisi, 46(4), 415 - 424. 10.1515/tjb-2020-0305
Chicago	Börekci Elif,Kılıç Mahmut,OZAN Zeynep,BÖREKÇİ Hasan,YILDIRIM Tekin,GÖÇMEN Yeşim,BAŞ Hatice Increased vitamin D binding protein levels are associated with irritable bowel syndrome. Türk Biyokimya Dergisi 46, no.4 (2021): 415 - 424. 10.1515/tjb-2020-0305
MLA	Börekci Elif,Kılıç Mahmut,OZAN Zeynep,BÖREKÇİ Hasan,YILDIRIM Tekin,GÖÇMEN Yeşim,BAŞ Hatice Increased vitamin D binding protein levels are associated with irritable bowel syndrome. Türk Biyokimya Dergisi, vol.46, no.4, 2021, ss.415 - 424. 10.1515/tjb-2020-0305
AMA	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H Increased vitamin D binding protein levels are associated with irritable bowel syndrome. Türk Biyokimya Dergisi. 2021; 46(4): 415 - 424. 10.1515/tjb-2020-0305
Vancouver	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H Increased vitamin D binding protein levels are associated with irritable bowel syndrome. Türk Biyokimya Dergisi. 2021; 46(4): 415 - 424. 10.1515/tjb-2020-0305
IEEE	Börekci E,Kılıç M,OZAN Z,BÖREKÇİ H,YILDIRIM T,GÖÇMEN Y,BAŞ H "Increased vitamin D binding protein levels are associated with irritable bowel syndrome." Türk Biyokimya Dergisi, 46, ss.415 - 424, 2021. 10.1515/tjb-2020-0305
ISNAD	Börekci, Elif vd. "Increased vitamin D binding protein levels are associated with irritable bowel syndrome". Türk Biyokimya Dergisi 46/4 (2021), 415-424. https://doi.org/10.1515/tjb-2020-0305